Abismuno Scientific Limited
Abismuno Scientific Limited emerges as a pivotal innovator in bispecific antibody research, contributing significantly to biomedical advancements. Specializing in engineering antibodies capable of simultaneous dual molecular targeting, Abismuno aspires to redefine therapeutic approaches by modulating multiple pathological pathways concurrently. This innovation paves the way for enhanced therapeutic specificity and efficacy, opening vistas for precise disease targeting and minimized therapeutic side effects. Positioned at the intersection of biotechnological and pharmaceutical research, Abismuno is dedicated to driving the future of targeted therapies, ensuring a transformative impact on global healthcare and medical treatment paradigms.
Founder(s) Name(s)
- Dr Wong Tsun-ting , Clarence (Assistant Professor, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University)
Achievement(s)
- PolyU MicroFund Venture(2022/2023)
Patent(s)
- Wong, C. T. T.*, Shao C. Peptidic Bispecific Antibody, Preparation and Application Thereof. 2022, US 63/269638.
Contact Information
